Clinical trial
Investigating the Effect of Post-dose Meal Timings and Water Volume at Dosing on the Pharmacokinetic Properties of Oral Zenagamtide in Participants With Overweight or Obesity
NCT07815067 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigating the Effect of Post-dose Meal Timings and Water Volume at Dosing on the Pharmacokinetic Properties of Oral Zenagamtide in Participants With Overweight or Obesity
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 7, 2026
- Completion date
- June 12, 2028
- Enrollment
- 320 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.